
BMC to procure 5 handheld air quality monitoring devices
To monitor pollutants and the Air Quality Index (AQI) levels around construction sites in Mumbai, in a pilot project, the Brihanmumbai Municipal Corporation (BMC) is set to procure five handheld ambient air quality monitoring devices at a cost of Rs. 5 lakh each.
The mobile equipment will be earmarked solely for the use of BMC engineers to maintain data and facilitate real time monitoring of AQI, particulate matters as well as pollutant gases.
'While the court has called for all construction sites to install their own monitoring sensors, it is also necessary that our engineers have their own monitoring mechanisms to ensure that the air quality levels are not breaching the normals. At a time when we are trying to implement several projects to mitigate air pollution, maintaining data of harmful gases and pollutants is very crucial. Therefore, we are planning to obtain five handheld monitoring devices which will monitor the PM 2.5, PM 10 levels as well as other indicators and calculate the overall AQI in and around construction sites,' a senior official told The Indian Express.
Currently, the city is home to nearly 25 monitoring stations of which 11 are operated by the MPCB, nine controlled by the SAFAR, while five are run by the BMC. Furthermore, the civic body has also rolled out plans to install five more new Continuous Ambient Air Quality Monitoring Stations (CAAQMS).
According to officials, the data from these hand-held monitoring devices will be used by civic engineers and officials in addition to the data from installed stations.
'Unlike the CAAQMS, which are quite big and require a lot of space, the new handheld devices are compact and can be transported easily wherever a need arises,' an official said, adding, 'Besides checking the pollution levels around construction sites, our engineers can also use these machines wherever a need is felt. For instance if the reading on the stations is quite high or if we receive complaints of foul smell etc.'
Recently, BMC's environment and climate change department floated a tender for the procurement of outdoor mobile ambient air quality monitoring devices. Estimated a cost of Rs 5 lakh each, these units will be equipped to monitor parameters of PM 2.5, PM 10, Sulphur Dioxide (SO2), Nitrogen Dioxide (NO2), Hydrogen Sulphide (H2S), Carbon Monoxide (CO), Methane (CH4), Total Volatile Organic Compounds (TVOC) as well as temperature, humidity and the moisture index.
'With the machines being expensive, we are planning to acquire only five machines in the pilot project. Once pressed into operations, we will observe their utility amongst our engineers and accuracy. If we observe positive trends, we will purchase more such hand-held monitoring devices in the future,' said an official.
For the record, earlier this month, the civic body has also instructed the developers to install approved sensor-based AQI monitoring stations at the construction within a period of 30 days. The instructions have been issued in line with the technologies from 15 companies which were shortlisted by the civic body, after an Expression of Interest (EOI) inviting units for particulate matters was floated in February.
'Even though our 27-point guideline for air pollution mitigation maintains that all construction sites must install stations to monitor air quality levels at site, we found that presently, only 10 percent of the construction sites were following the directives. However, in these cases, it was observed that the readings from the machines were not reliable. Therefore, we had floated an EOI to streamline and standardise the type and quality of machines in a bid to ensure accurate AQI. Having now finalised technologies from 15 companies, we have informed all construction sites to install these monitoring stations,' said a senior civic official.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Standard
4 hours ago
- Business Standard
Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane
Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets. Xbrane Biopharma AB is a biotechnology company. It develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSources integrated drug substance and drug product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbranes global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbranes latest funding round, reinforcing the long-term alignment between the two companies. Neeraj Sharma, managing director & CEO of OneSource Specialty Pharma, said: The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbranes proven success in biosimilar development, combined with OneSources fully integrated biologics platform, creates a strong platform for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the worlds leading biotech companies. OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. On a consolidated basis, OneSource Specialty Pharma reported net profit of Rs 98.50 crore in Q4 March 2025 as against net loss of Rs 40.17 crore in Q4 March 2024. Net sales surged 482.38% YoY to Rs 425.95 crore in Q4 March 2025.


New Indian Express
6 hours ago
- New Indian Express
Axiom-4 mission with Indian astronaut postponed again after SpaceX detects leak in rocket
BENGALURU: The Axiom-4 mission, which was scheduled to carry Indian astronaut Shubhanshu Shukla and three others to the International Space Station (ISS) on Tuesday, has been postponed again, marking the second delay in the launch. The launch was earlier deferred from 10 June to 11 June due to adverse weather conditions. This time, a Liquid Oxygen (LOx) leak in SpaceX's Falcon 9 rocket has caused the delay. The issue remains unresolved, and a new launch date has not yet been announced. SpaceX confirmed the postponement via X. The Axiom Space social media team said: "Standing down from the Falcon 9 launch of Ax-4 to the Space Station to allow additional time for SpaceX teams to repair the LOx leak identified during post static fire booster inspections. Once complete – and pending Range availability – we will share a new launch date." Notably, ISRO is collaborating with NASA for the mission. It has invested Rs 550 crore in the project and has deputed Group Captain Shukla, one of the four selected astronauts, as the mission pilot. He has been tasked with docking the spacecraft to the ISS during the 14-day mission.
&w=3840&q=100)

Business Standard
8 hours ago
- Business Standard
Best of BS Opinion: India is faced with a strategic turning point
There's a moment in every fight, every conflict, every country's economic strategy, where the shield cracks. The noise outside gets louder, the sand underfoot more uncertain. It's not just a question of survival anymore. It's what you do next. You lunge, adapt, recalibrate or you're trampled. The same test of resolve applies now across India's economic, strategic and scientific frontiers, where shields once considered strong are showing signs of stress. Like gladiators, the dent in the armour is visible and now we must choose when and where to strike. Let's dive in. China has just driven a spike into India's rare earth supply shield. With new export controls on vital metals and magnets, India's green and defence ambitions are exposed. Japan faced this once and countered swiftly with strategic deals and stockpiles. India, though, is only starting to build its moat, through ventures like KABIL and domestic processing, notes our first editorial. But these are still early moves. Without stronger regional alliances and a clear long-term plan, Indian manufacturing could be caught off guard. In space, however, India's aim is high and its resolve stronger. Group Captain Shubhanshu Shukla is poised to soar aboard SpaceX's Falcon rocket under the Axiom-4 mission. Supported by Isro, this journey to the International Space Station will test the limits of India's readiness for manned missions, highlights our second editorial. It's a proving ground for Gaganyaan, and perhaps even future space habitats. What Shukla brings back, in terms of data, insight, and instinct, could patch the cracks before the next big lift-off. Back on Earth, the fiscal shield is looking thin again. A K Bhattacharya writes that revenue overestimation is back after a four-year break. Personal income-tax collections have missed by Rs 74,000 crore. Spending has been reined in. And while capital expenditure was protected, the crack in the armour, 6.5 per cent GDP growth, down from 9.2 per cent, can't be missed. Deep Kapuria flags another chink: the QCO regime meant to upgrade product quality is under strain. With only 769 out of 23,000 BIS standards enforced, and trade partners grumbling, India's quality crusade is caught between ambition and implementation. The solution? Less brute force, more finesse: decentralised certification, smarter MRAs, and a phased, strategic charge, not a wild swing. And when it comes to the marketing colosseum, Siddhesh Joglekar reviews Marketing Mixology: Four Essential Ingredients for Marketing Success by Ambi Parameswaran — a swift, jargon-free training manual for modern brand warriors. Less textbook, more battle guide. Whether you're a fresh grad or a founder, the book is a well-timed reminder that even when the battlefield shifts, the fundamentals of storytelling, empathy, and timing stay firm.